Cystic fibrosis in Australia, 2009: results from a data registry

Cystic fibrosis (CF) is the most common life-shortening, autosomal recessive disease affecting people of European ancestry. It results in multisystem disease, predominantly affecting the lungs and the gastrointestinal system.

Previously, it was reported that the incidence of CF in Australia was about 1 in 2800 live births and about 1 in 25 people were carriers of a genetic mutation responsible for CF.

Overseas studies have shown that, in the 1960s, median survival time with CF was about 10 years but is now more than 35 years. Factors thought to have contributed to improved survival are newborn screening, management of patients in specialist CF centres, improvement in treatment of neonatal meconium ileus and pancreatic insufficiency, better antibiotics, and more effective approaches to nutrition and airway clearance.

There is limited information available about the demographics and clinical outcomes of Australians with CF. The aim of our report is to describe the demographics, clinical features of disease and outcomes among people with CF in Australia using data submitted to the Australian Cystic Fibrosis Data Registry (ACFDR) in 2009 and to make an updated estimate of disease incidence.

Methods

Data registry

In 1998, Cystic Fibrosis Australia (CFA) supported the development of a data registry in Australia and New Zealand, based on the American Cystic Fibrosis Foundation Patient Registry. The purpose of the registry was to allow measurement of the demographics, morbidity and mortality of the CF population to increase awareness about CF, improve quality of patient care through comparisons of CF centres, and facilitate research. People with CF are identified through centres that also coordinate data submission. Recommended practice in Australia is for people with CF to be referred to a CF centre, which is usually a multidisciplinary specialist team attached to a teaching hospital.

Since 2005, data entry has been via a web-based form, directly into the registry’s Microsoft SQL database (Microsoft Corporation, Redmond, Wash, USA). Data are de-identified at submission and given a unique identifier that includes a CF-centre code. Centres submit either annual information or information for each patient visit. Patients who transfer from one centre to another are tracked using identifiers, sex and date of birth, and their data can be electronically transferred.

Analysis

Data for this report were extracted from information submitted by all CF centres in 2009. Patients who reside in the Northern Territory and Australian Capital Territory have shared-care with neighbouring states, and their data are submitted by the CF centre that they attend. Demographic and diagnosis information, pulmonary function test results, anthropometric measurements, microbiological culture findings, hospitalisation rates, and information on treatments, complications, mortality and transplantation were collected. If multiple entries had been made for a patient, the measurement of best pulmonary function and the highest values for height and weight for the year were used. Standard deviation scores (z scores) were calculated using United States National Center for Health Statistics and Centers for Disease Control and Prevention normalised growth reference values for height, weight and body mass index (BMI). We only included pulmonary function test results for patients over 6 years of age and used two pulmonary function prediction equations that were appropriate for age.

We estimated incidence using 5-year birth cohorts for 2004–2008 and births data from the Australian Bureau of Statistics. We considered patients to be children up to 11 years of age, adolescents if they were 12–17 years and adults from age 18 years. We reported children’s nutritional status for the 2–5-years and 6–11-years age groups. The Student t test was
used to compare lung function, z scores and BMI. \( P < 0.05 \) was considered to be statistically significant.

**Ethics approval**

Contributing centres received approval from local ethics committees to enter data in accordance with National Health and Medical Research Council guidelines. Most patients and families had given written informed consent for data collection (not all ethics committees required individual consent).

**Results**

In 2009, data on 2986 patients with CF (1430 female; 48%) from 11 paediatric CF centres, 10 adult centres and one mixed paediatric and adult centre were reported to the ACFDR. Paediatric centres ranged in size from 56 to 317 patients, and adult centres from 46 to 280 patients. Eighty-three percent of patients (65/78) who were newly diagnosed with CF were diagnosed through neonatal screening. Thirteen patients were diagnosed after 12 months of age; four were adults, two of whom were aged >35 years. Among the two-thirds of patients for whom a CF gene mutation was reported, most had at least one copy of the p.F508del (most common) mutation and just over half were homozygous. Fourteen people died, nine of whom were adults, including four aged over 35 years. Fourteen people, including four children, underwent lung transplantation. The incidence of CF, averaged over 5 years of ACFDR data to 2008, was one in 2986 (95% CI, 2735–3288) Australian births.

The median age for all patients was 17.6 years (mean, 19.1 years) for males, 18.1 years and for females, 17.1 years. About half were adults (1451; 49%), and one-fifth were 30 years or older (586; 20%). Of the 749 adults for whom marital status was reported, 123 men and 154 women were married or in a de-facto relationship and 114 were parents (49 men). In 2009, 22 adult women and two adolescents had a pregnancy. Twelve resulted in live births, six were pregnant at the time of data entry, three had miscarried and the status of three was unknown. Of 550 adults for whom educational status was reported, 344 had completed high school and 153 possessed a tertiary qualification. Most adults were working or studying (448/639).

**Pulmonary function**

Percentage predicted forced expiratory volume in one second (FEV\(_1\) % predicted) decreased with increasing age (Box 1). The mean FEV\(_1\) % predicted for children and adolescents aged 6–17 years was 92.8% (SD, 18.2%) and for adults was 66.4% (SD, 22.2%). More than 50% of children and adolescents, but only 15% of adults, had an FEV\(_1\) % predicted in the normal range (Box 2). Notably, there was a wide range of lung function in all age groups. FEV\(_1\) % predicted did not differ by sex for children (boys, 92.9% [SD, 18.3%]; girls, 92.7% [SD, 18.2%]; \( P = 0.87 \)) or for adults (men, 66.0% [SD, 23.3%]; women, 68.8% [SD, 20.8%]; \( P = 0.55 \)).

**Pulmonary microbiology**

Specimens for microbiological culture were mostly sputum across all age groups, but samples from broncho-

---

**1 Mean FEV\(_1\) % predicted in Australian patients with cystic fibrosis aged 6 to 44 years, 2009**

Error bars represent 95% confidence intervals. FEV\(_1\) % predicted = percentage predicted forced expiratory volume in one second. ◆

**2 Severity of lung disease* in Australian patients with cystic fibrosis, 2009**

FEV\(_1\) % predicted = percentage predicted forced expiratory volume in one second. * Categories of severity of impairment of FEV\(_1\): normal — FEV\(_1\) % predicted > 90%; mild — FEV\(_1\) % predicted 70% to < 90%; moderate — FEV\(_1\) % predicted 40% to < 70%; severe — FEV\(_1\) % predicted < 40%. ◆

**3 Findings from microbiological culture of sputum or bronchoscopy samples* from Australian patients with cystic fibrosis, 2009**

* Number and percentage of patients with at least one culture positive for the organism. ◆
Methicillin-sensitive *Staphylococcus aureus* infection was common among all age groups, and *Haemophilus influenzae* infection was also common among children (Box 3). The prevalence of *Pseudomonas aeruginosa* infection increased with increasing age. *Burkholderia cepacia* complex and methicillin-resistant *S. aureus* (MRSA) infection were relatively uncommon among all age groups (Box 3).

### Nutritional status

Overall, young children aged 2–5 years were found to be normally nourished, but with increasing age, z scores for both weight and height decreased (Box 4). Adolescent males were more poorly nourished than adolescent females, with lower z scores for weight (*P* = 0.05) and BMI (P = 0.02). Mean BMI for adults was 22.5 kg/m² (SD, 3.3). BMI was higher in men than in women (23.1 kg/m² [SD, 3.3] v 21.9 kg/m² [SD, 3.2]; P < 0.001). Mild undernutrition (BMI, 18 to < 20 kg/m²) was seen in 13.3% of men and 20.0% of women. Severe undernutrition (BMI, < 18 kg/m²) was evident in 3.7% of men and 7.8% of women.

### Complications

With increasing age of patients, there was an increase in the frequency of pulmonary complications such as haemoptysis, pneumothorax, and respiratory failure (Box 5). A similar pattern was seen with gastro-oesophageal reflux (both symptomatic and endoscopically proven), abnormal biochemical liver function tests, cirrhosis and pancreatitis. CF-related diabetes (intermittent) requiring insulin therapy was not seen in children. It was evident as a complication among adolescents and was most common in adults. Low bone density increased with age, yet the fracture rate for all age groups was low.

### Health care utilisation

Attendances for outpatient review were relatively constant over all age groups. The proportion of patients hospitalised for all CF-related indications was similar in children aged 2–5 years compared with those aged 6–11 years, but higher for adolescents and adults (Box 6). Of all patients admitted, 82% (897/1091) were admitted for respiratory complications. The proportion of patients requiring two or more respiratory-related hospitalisations was higher among adolescents (115/502; 23%) and adults (167/748; 23%) compared with children (148/1034; 14%).

---

**4 Nutritional status of Australian children and adolescents with cystic fibrosis, 2009**

<table>
<thead>
<tr>
<th></th>
<th>Young children (2–5 years)</th>
<th>Older children (6–11 years)</th>
<th>Adolescents (12–17 years)</th>
<th>All children and adolescents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>z score, mean (SEM)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Height</strong></td>
<td>0.02 (0.06)</td>
<td>-0.30 (0.05)</td>
<td>-0.36 (0.05)</td>
<td>-0.25 (0.03)</td>
</tr>
<tr>
<td><strong>Weight</strong></td>
<td>0.34 (0.06)</td>
<td>-0.13 (0.04)</td>
<td>-0.25 (0.05)</td>
<td>-0.07 (0.03)</td>
</tr>
<tr>
<td><strong>Body mass index</strong></td>
<td>0.35 (0.06)</td>
<td>0.12 (0.04)</td>
<td>-0.10 (0.04)</td>
<td>0.13 (0.03)</td>
</tr>
</tbody>
</table>

**5 Medical complications in Australian patients with cystic fibrosis, 2009**

<table>
<thead>
<tr>
<th></th>
<th>Children (0–11 years)</th>
<th>Adolescents (12–17 years)</th>
<th>Adults (&gt; 18 years)</th>
<th>All age groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total number of patients</strong></td>
<td>951</td>
<td>448</td>
<td>697</td>
<td>2096</td>
</tr>
<tr>
<td><strong>Major haemoptysis</strong></td>
<td>2 (0.2%)</td>
<td>12 (2.7%)</td>
<td>46 (6.6%)</td>
<td>60 (2.9%)</td>
</tr>
<tr>
<td><strong>Massive haemoptysis</strong></td>
<td>0</td>
<td>2 (0.4%)</td>
<td>5 (0.7%)</td>
<td>7 (0.3%)</td>
</tr>
<tr>
<td><strong>Bronchial artery embolisation</strong></td>
<td>4 (0.4%)</td>
<td>2 (0.4%)</td>
<td>14 (2.0%)</td>
<td>20 (1.0%)</td>
</tr>
<tr>
<td><strong>Pneumothorax</strong></td>
<td>1 (0.1%)</td>
<td>1 (0.2%)</td>
<td>11 (1.6%)</td>
<td>13 (0.6%)</td>
</tr>
<tr>
<td><strong>Oxygen use</strong></td>
<td>2 (0.2%)</td>
<td>10 (2.2%)</td>
<td>19 (2.7%)</td>
<td>31 (1.5%)</td>
</tr>
<tr>
<td><strong>Non-invasive ventilation</strong></td>
<td>4 (0.4%)</td>
<td>8 (1.8%)</td>
<td>12 (1.7%)</td>
<td>24 (1.3%)</td>
</tr>
<tr>
<td><strong>Gastro-oesophageal reflux (treated)</strong></td>
<td>74 (7.8%)</td>
<td>66 (14.7%)</td>
<td>196 (28.1%)</td>
<td>336 (16.0%)</td>
</tr>
<tr>
<td><strong>Gastro-oesophageal reflux (endoscopically proven)</strong></td>
<td>11 (1.2%)</td>
<td>17 (3.8%)</td>
<td>26 (3.7%)</td>
<td>54 (2.6%)</td>
</tr>
<tr>
<td><strong>Abnormal liver function tests</strong></td>
<td>59 (6.2%)</td>
<td>72 (16.1%)</td>
<td>195 (28.0%)</td>
<td>326 (15.6%)</td>
</tr>
<tr>
<td><strong>Cirrhosis and/or portal hypertension</strong></td>
<td>10 (1.1%)</td>
<td>28 (6.3%)</td>
<td>30 (4.3%)</td>
<td>68 (3.2%)</td>
</tr>
<tr>
<td><strong>Pancreatitis</strong></td>
<td>1 (0.1%)</td>
<td>4 (0.9%)</td>
<td>15 (2.2%)</td>
<td>20 (1.0%)</td>
</tr>
<tr>
<td><strong>Insulin-dependent diabetes (chronic)</strong></td>
<td>5 (0.5%)</td>
<td>61 (13.6%)</td>
<td>144 (20.7%)</td>
<td>210 (10.0%)</td>
</tr>
<tr>
<td><strong>Insulin-dependent diabetes (intermittent)</strong></td>
<td>0</td>
<td>5 (1.1%)</td>
<td>16 (2.3%)</td>
<td>21 (1.0%)</td>
</tr>
<tr>
<td><strong>Other glucose abnormalities</strong></td>
<td>12 (1.3%)</td>
<td>38 (8.5%)</td>
<td>100 (14.3%)</td>
<td>150 (7.2%)</td>
</tr>
<tr>
<td><strong>Osteoporosis</strong></td>
<td>2 (0.2%)</td>
<td>6 (1.3%)</td>
<td>66 (9.5%)</td>
<td>77 (3.7%)</td>
</tr>
<tr>
<td><strong>Osteopenia</strong></td>
<td>3 (0.3%)</td>
<td>15 (3.3%)</td>
<td>174 (25.0%)</td>
<td>192 (9.2%)</td>
</tr>
<tr>
<td><strong>Fracture this year</strong></td>
<td>0</td>
<td>2 (0.4%)</td>
<td>8 (1.1%)</td>
<td>10 (0.5%)</td>
</tr>
<tr>
<td><strong>Cancer</strong></td>
<td>1 (0.1%)</td>
<td>2 (0.4%)</td>
<td>9 (1.3%)</td>
<td>12 (0.6%)</td>
</tr>
</tbody>
</table>

---

**6 Health care utilisation among Australian patients with cystic fibrosis (CF), 2009**

<table>
<thead>
<tr>
<th></th>
<th>0–1</th>
<th>2–5</th>
<th>6–11</th>
<th>12–17</th>
<th>&gt; 18</th>
<th>All age groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No. of outpatient visits per patient, median (25th, 75th centile)</strong>*</td>
<td>5 (3, 7)</td>
<td>4 (3, 5)</td>
<td>4 (3, 6)</td>
<td>4 (3, 6)</td>
<td>4 (2, 7)</td>
<td>4 (2, 6)</td>
</tr>
<tr>
<td><strong>No. of hospitalisations per patient for all CF-related indications, mean (SEM; range)</strong></td>
<td>0.86 (0.09; 0–6)</td>
<td>0.74 (0.05; 0–7)</td>
<td>0.75 (0.05; 0–9)</td>
<td>1.20 (0.08; 0–10)</td>
<td>1.08 (0.06; 0–13)</td>
<td>0.96 (0.03; 0–13)</td>
</tr>
<tr>
<td><strong>Patients admitted, all CF-related indications, no./total (%)</strong></td>
<td>77/152 (50.7%)</td>
<td>180/370 (48.6%)</td>
<td>212/512 (41.4%)</td>
<td>261/502 (52.0%)</td>
<td>361/748 (48.3%)</td>
<td>1091/2284 (47.8%)</td>
</tr>
</tbody>
</table>

* Based on 2799 patients. † Based on 2284 patients (three major adult hospitals omitted due to incomplete or missing data).
Discussion

Our analysis of 2009 data provided to the ACFDR indicates that health outcomes for Australians with CF have continued to improve, but increasing age has a progressive impact on health and health care utilisation. As disease complications increase, patients need to balance the challenge of the pursuit of a longer and fulfilled life with high treatment demands.

There are about 3200 people with CF in Australia, as we estimate that the 2986 patients identified are about 90% of the total number of people with CF in Australia. The incidence of CF in Australia now approaches one per 2986 patients, compared to 1 in 3000 births. Most new diagnoses of CF in 2009 were made through the Australia-wide newborn screening program. However, diagnosis is still delayed in some children born since implementation of the screening program, and four people were diagnosed as adults. Early diagnosis is expected to be associated with improved outcomes.

While we have estimated that the ACFDR covered 90% of people with CF in 2009, some underrepresentation of patients was evident in the ACFDR report, and reporting has varied. Our estimate is based on opinions of CF centres and comparisons with other data. Comparisons between total deaths by age group in the ACFDR with any ICD-10 (International Classification of Diseases, 10th revision) code indicating CF from the Australian Institute of Health and Welfare (AIHW) National Mortality Database suggest some undercoverage in adult age groups, possibly due to loss to follow-up when private care is chosen, or after lung transplantation, for which care is exclusively at transplant centres. We plan to include analysis of supplementary data from transplant centres in future registry reports. Our confidence in the completeness of data for Australian children with CF is based on the system of referral to CF centres following diagnosis through newborn screening programs. With the enthusiasm and goodwill of many, complete population coverage including all adults and those who have undergone lung transplantation will be achieved within several years. The overall level of coverage achieved in Australia compares favourably with that of overseas data registries. Recent improvements have been online data entry and the generation of patient reports suitable for clinical care. Data registries need to meet a quality standard to be effective, and this requires significant resources. While the ACFDR is well established, annual data collection is an unfunded burden for CF centres and failure to collect data would threaten the registry’s contribution to further improving outcomes for people with CF through research and better care.

The development of data registries allows comparison of outcomes between CF centres within countries and internationally to identify practices that will enhance health. For example, the finding that children with CF from Victoria had better survival than UK patients was attributed to the model of coordinated specialist care in Victoria and the development of specialist CF care centres worldwide. The most recent study of life expectancy among patients with CF in Australia found that from 1979 to 2005 the mean age at death increased from 12.2 years to 27.9 years for males and from 14.8 to 25.3 years for females. The ACFDR has attempted only a preliminary survival analysis because of uncertainty about ascertainment of all deaths (unpublished data); however, they have begun a project comparing deaths reported to the ACFDR with deaths reported to the AIHW National Mortality Database to allow more accurate survival analyses. Centre-to-centre comparisons are now well established in the US, and have been available for Australian CF centres for the past 3 years. However, their validity is dependent on there being complete and high-quality data and standardised methods for comparison of health status. This requires resources that are not readily available for this activity in CF centres.

Progressive respiratory disease is the major cause of morbidity and mortality among people with CF. Despite the absence of symptoms of CF, there is evidence of pulmonary disease early in life. Bronchoscopy specimens have shown evidence of airway infection and inflammation in young children with CF, and computed tomography scans have shown bronchiectasis in 22% of preschool children with CF. FEV1 is the single best predictor of mortality. Our data indicate that FEV1 is relatively normal between 6 and 11 years of age, with an increase in the rate of decline in FEV1 between 12 and 25 years. This is similar to the pattern of maximal decreases in FEV1 in adolescence shown by US data. Targeted interventions for children before they enter adolescence may be the key to establishing further improvements in morbidity and survival associated with CF.

This evidence for more severe respiratory disease in adolescence is associated with a doubling of the prevalence of P. aeruginosa infection among adolescents compared with children. Chronic P. aeruginosa infection is a risk factor for poorer outcome. Implementation of strategies to avoid chronic P. aeruginosa infection earlier in childhood may lead to improved lung function in adulthood. The rates of isolation of MRSA and B. cepacia complex are low but increase with age. Cross-infection between patients is a potential problem for CF centres, as these organisms are associated with poorer outcomes and can be a contraindication for transplantation, so implementation of infection control policies is standard practice.

A consequence of improved life expectancy is that 50% of people with CF are now adults. Adulthood among patients with CF is associated with more severe lung disease, poorer nutritional status and more CF-related complications such as haemoptysis, pneumothorax, diabetes, metabolic bone disease and the consequences of male infertility. Despite this burden of disease and associated treatment demands, we found that most adults with CF work or study and many establish relationships and families. As it is estimated that more than 90% of children with CF will reach adulthood, caring for adolescents requires a focus which allows for minimal interruption of schooling while allowing people with CF to achieve their potential. The CF care team needs to consider flexible access to care for the individual who is continuing to study, work and develop...
lifelong relationships.\textsuperscript{25} Helping adolescents and young adults to accept demanding treatment programs is a challenge for CF teams.

People with CF require lifelong medical support, and new adult-specific CF centres have emerged over the past 25 years. Recently published Australian guidelines for CF care\textsuperscript{6} recommend that patients be reviewed quarterly; but, according to the ACFDR, half the population received fewer reviews than this. Furthermore, hospitalisation in 2009 equated to about 3000 inpatient episodes (about 30 000 occupied bed-days), of which 80% were for treatment of respiratory complications. The national annual health system cost for CF care has been estimated to be around A$67 million.\textsuperscript{26} The distribution of costs included patient costs, 58%; pharmaceuticals, 29%; medical services, 10%; complications, 2%; and diagnostic tests, 1%. ACFDR data indicate that the burden of care increases as patients age, so CF health care planning is urgently required — particularly given the increase in numbers of adults with CF.\textsuperscript{11,12} The forthcoming national health reforms provide an opportunity for a coordinated approach to health service planning for CF.\textsuperscript{27}

\textbf{Acknowledgements:} We acknowledge the support of each of the participating CF centres, including centre directors, CF care coordinators and data entry personnel; CFAs for financial support; and their staff, in particular: Mr Terry Stewart, Chief Executive Officer; state CF organisations for additional financial support; Roche Pharmaceuticals and Solvay Pharmaceuticals for past and present financial support.

Scott Bell acknowledges the support of the Office of Health and Medical Research (Health Research Fellowship), Queensland Health.

\textbf{Competing interests:} Geoff Sims has received consultancy fees for the management of the ACFDR. Scott Bell, James Martin, Phillip Robinson, Gerard Ryan and Geoff Sims have received support from CFA for travel and, when required, accommodation to attend ACFDR Medical Advisory Committee Meetings held in Sydney.

Received 7 Jun 2011, accepted 17 Aug 2011.